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Synthesis of two new water-soluble mixed ligand [Pd(bpy)(dahmp)]Cl and [Ag(bpy)(Hdahmp)]NO3 complexes (dahmp and
Hdahmp are the deprotonated monoanion and the protonated neutral 4,6-diamino-5-hydroxy-2-mercaptopyrimidine, resp.) is
reported. The composition of the reported complexes was discussed on the bases of IR, 1H NMR, and mass spectra, as well as
conductivity and thermal measurements. The reported complexes display a signiﬁcant anticancer activity against Ehrlich ascites
tumor cells (EACs). The higher activity of these complexes with their higher conductivity values corresponds to their complete
ionization in aqueous solution.
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1. INTRODUCTION
Currently, cisplatin is being used as an anticancer agent
in several human cancers, particularly, testicular and ovar-
ian cancers [1, 2]. Side eﬀects, especially nephrotoxicity, of
this drug limit its widespread use in high dose [3]. The
need to develop new complexes with reduced nephrotox-
icity and higher activity has stimulated the synthesis of
many new complexes. Over the past years, a renewed inter-
est in Pd(II) complexes as potential anticancer agents has
developed. Though a number of interesting Pd(II) targets
have been investigated [4–7], the biological utility of such
agents continues to be questioned, this may be due to the
poor solubility of common Pd(II) complexes under physio-
logic conditions. Many studies, including nucleic and amino
acid derivatives, showed that 2-mercaptopyrimidine and 2-
mercapto-4-aminopyrimidine are able to inhibit the synthe-
sis of t-RNA [8]. Thus, they may act as valuable substrates
in the synthesis of antitumor chemotherapeutic agents [9].
Also, the eﬀect of 2-mercaptopyrimidine-5-carboxylic acid
and S-analogy of pyrimidinic bases on oral epidermoid hu-
man carcinoma (KB) have been reported [10, 11].
As a continuation of our research in 4,6-diamino-5-
hydroxy-2-mercaptopyrimidine complexes and their biolog-
ical activities [12], in this research, we report the com-
plexesobtainedfromthereactionof4,6-diamino-5-hydroxy-
2-mercaptopyrimidine (Hdahmp) with [Pd(bpy)Cl2]a n d
[Ag(bpy)(H2O)2]NO3.TheyhavebeeninvestigatedusingIR,
1HNMR, and mass spectra, conductivity and thermal mea-
surements. In addition, the anticancer activity of these com-
plexes against Ehrlich ascites tumor cells (EACs) has been re-
ported.
2. EXPERIMENTAL
2.1. Materialandmethods
All manipulations were performed under aerobic conditions
using 4,6-diamino-5-hydroxy-2-mercaptopyrimidine and all
otherreagents(Merck)asreceived.[Pd(bpy)Cl2]wassynthe-
sized by the literature method [13].2 Metal-Based Drugs
The cells of Ehrlich ascites (EACs) tumor were obtained
from National Cancer Institute (Cairo, Egypt). After harvest-
ing and preparation of the cells, their total number and via-
bility were determined by counting using Trypan blue [14].
2.2. Instrumentation
Microanalyses were determined by the Micro Analytical Unit
(Cairo University, Cairo, Egypt). Electronic spectra were
recorded using a Unicam UV2–100 U.V.-vis. Spectrometer. IR
spectra were measured as KBr discs on a Matson 5000 FT-
IR spectrometer (Cairo University). 1H NMR spectra were
measured on a Varian Gemini WM-200 spectrometer (Laser
Centre, Cairo University). Thermal analysis measurements
were made in the 20–800◦C range at the heating rate of 10◦C
min−1, using α-Al2O3 as a reference, on a Shimadzu Ther-
mogravimetric Analyzer TGA-50. Conductimetric measure-
ments were carried out at room temperature on a YSI Model
32 conductivity bridge. Mass spectra were recorded on a
Matson MS 5988 spectrometer (Micro Analytical Unit, Cairo
University).
2.3. Synthesisofcomplexes
2.3.1. [Pd(bpy)(dahmp)]Cl·H2O
To a stirred suspension of [Pd(bpy)Cl2] (0.17g, 0.5mmol)
in methanol-benzene (3 : 2, V/V) (15cm3), was added a
methanolic solution of KOH (0.055g, 1mmol) contain-
ing Hdahmp (0.08g, 0.5mmol). The resulting suspension
was stirred for two days and a brown complex was ob-
tained. It was ﬁltered oﬀ, washed with water and methanol,
and then air-dried. Conductivity data (10−3 M in DMF):
ΛM = 97.0ohm−1 cm2 mol−1.E l e m e n t a lAnal.C a l c .f o r
C14ClH15N6O2SPd: C, 35.53; H, 3.17; N,17.76; S, 6.77; Cl,
7.51. Found C, 35.72; H, 3.11; N, 17.71; S, 6.85; Cl, 7.63.
2.3.2. [Ag(bpy)(Hdahmp)]NO3
Silver nitrate (0.087g, 0.5mmol) in water (2cm3)w a s
added to bpy (0.078g, 0.5mmol) in methanol (35cm3)t o
produce a colorless solution, to which Hdahmp (0.08g,
0.5mmol) was added. The reaction mixture was stirred in
dark for 3 hours to produce a pale brown solid. It was ﬁl-
tered oﬀ, washed with little water, methanol, and diethyl
ether, then dried in vacuo. Conductivity data (10−3 Mi n
DMF): ΛM = 60.0ohm−1 cm2 mol−1.E l e m e n t a lAnal.C a l c .
for C14H14N7O4SAg: C, 34.72; H, 2.89; N, 20.25; S, 6.61.
Found C, 34.54; H, 2.78; N, 20.00; S, 6.42.
2.4. Conductivitymeasurements
The conductivity values for [Pd(bpy)(dahmp)]Cl and [Ag-
(bpy)(Hdahmp)]NO3 were determined. The compounds
were dissolved in water and the measurements were done at
concentrations;1,0.8,0.6,0.4,and0.2mM.Theconductance
values (ΛM) were calculated and plotted against concentra-
tion [15].
2.5. AnticanceractivityagainstEhrlichascites
carcinomainmice
All the compounds were screened for their anticancer
activity by dissolving samples in minimum amount of
DMSO (Hdahmp) or water (complexes) and diluting with
phosphate-buﬀered saline (PBS; pH = 7.2). The anticancer
studies using Ehrlich ascites tumor cells (EACs) were car-
ried out by incubating 0.2mL of cells IP. All the treat-
ments started 24 hours after inoculation for 45 days. The
tumor-bearing mice were divided into three groups. Group
(1) is the standard one that received the 5-ﬂorouracil
[16] (5-fu; 20mg/kg/day of mice) for comparison. Group
(2) received Hdahmp, [Pd(bpy)(dahmp)]Cl, [Ag(bpy)-
(Hdahmp)]NO3 complexes (0.01mg/mice/day). Group (3)
is the control one received physiological saline (0.9% sodium
chloride).
3. RESULTS AND DISCUSSION
3.1. Synthesisofcomplexes
Table 1 lists two new complexes of 4,6-diamino-5-hydroxy-
2-mercaptopyrimidine(Hdahmp).Theelementalanalysesof
the isolated complexes agree with the assigned formula. The
conductivities (ΛM) in DMF at room temperature showed
the electrolytic character of these complexes [4, 16].
The complex [Pd(bpy)(dahmp)]Cl was prepared from
[Pd(bpy)Cl2]andHdahmpinmethanol-benzeneinpresence
ofaqueousbase,while[Ag(bpy)(Hdahmp)]+ wasmadefrom
aqueous AgNO3 with bpy and Hdahmp in methanol.
The complexes are powder-like, stable in the normal lab-
oratory atmosphere, and soluble in water, DMF, or DMSO.
We had hoped to characterize the structure of one of the
complexesbysingleX-raycrystallography,butwerethwarted
on numerous occasions by very small crystal dimensions.
Thus, the characterization of these complexes was based on
the physical and spectroscopic techniques.
3.2. Vibrationspectra
The characteristic IR bands observed and the vibration as-
signmentsof4,6-diamino-5-hydroxy-2-mercaptopyrimidine
(Hdahmp) complexes are reported in Table 1. The spectrum
of Hdahmp supports the existence of the thione form in
the solid phase (Scheme 1). This can be attributed to the
presence of ν(NH) stretch at 2970cm−1 [17], the absence of
ν(SH) near 2600cm−1, and the production of the character-
istic thioamide bands due to extensive coupling of δ(NH),
ν(C=N),ν(NCS),andν(C=S)at1652,1562,1455,and(1375,
1268, 1177)cm−1,r e s p e c t i v e l y[ 18–20].
In the spectrum of [Pd(bpy)(dahmp)]Cl, the stretching
vibration ν(OH) at 3305cm3 in the free ligand is missing in
the complex [21]. The bands at 3390 and 3185cm−1,a r i s -
ing from νs(NH2)a n dνas(NH2), respectively [21], in the
free ligand are shifted to lower wave numbers upon com-
plexation [21, 22]. The bands arising from ν(C=N), ν(NCS),
and ν(C=S) are not aﬀected while the bands arising from
ν(NH) and δ(NH) stretches are slightly shifted to lower
wave number in the complexes. This suggests that HdahmpS. I. Mostafa and F. A. Badria 3
Table 1: Spectral data of Hdahmp and its complexes.
IR spectral data
Complexes ν(OH) νs(NH2) νas(NH2) δ(NH) ν(C=C)
ν(C=N)
ν(NCS)
ν(CN)
ν(M–O) ν(M–N) ν(NCS)
ν(CS)
[Pd(bpy)(dahmp)]Cl — 3397
3360
3165 1640 1556 1450
1362
524 409 1255
1176
[Ag(bpy)(Hdahmp)]NO3 3308 3396 3171 1650 1543 1479
1396
— 412
372∗ 1277
1207
∗ν(Ag–S).
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Scheme 1: 4,6-diamino-5-hydroxy-2-mercaptopyrimidine (Hdah-
mp).
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Scheme 2: Structure of [Pd(bpy)(dahmp)]Cl.
acts as a mononegative bidentate ligand, coordinating the
metal ion through the deprotonated hydroxyl and amino
N(6)H2 groups, without any participation of the thione sul-
fur or cyclic nitrogen atoms in coordination [23]. This fea-
ture is further supported by the observation that a band
near 1178cm−1 arises from ν(C=S) stretch that remains
unchanged [18]( Scheme 2). The vibrational spectrum of
[Ag(bpy)(Hdahmp)]NO3 suggests the participation of the
thionesulphurandthecyclicN(3)incoordinationduetothe
shift observed in the ν(C=S) and ν(N–C=S) stretching vibra-
tions (Scheme 3). This suggestion is supported by the slight
shift of ν(NH) and δ(NH) to lower wave number with the
existence of νs(NH2), νas(NH2), and ν(OH) stretches more
or less in the same position as in the free ligand [18, 22, 24].
Also, the bands of the free bpy ligand near 740cm−1 are
shifted to higher frequencies in the complexes (773cm−1)
[4, 25].
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Scheme 3: Structure of [Ag(bpy)(Hdahmp)2]NO3.
The spectrum of [Ag(bpy)(Hdahmp)]NO3 shows new
strong band near 1370cm−1 assigned to the ionic uncoor-
dinated NO
−
3 [16, 26, 27].
3.3. Electronicspectra
The electronic spectrum of [Pd(bpy)(dahmp)]+ complex
shows bands at 475 and 326nm due to 1A1g → 1B1g and
1A1g → 1E1g, transitions in a square-planar conﬁguration
[4, 23, 27]. Also, the spectrum of [Ag(bpy)(Hdahmp)]+
showsbandsat467,382,and277nm;thelattertwomayarise
from charge transfer of the type ligand (π) → b1g (Ag+)a n d
ligand (σ) → b1g (Ag+), respectively, in a typically distorted
square planar environment around the metal ion [4, 28, 29].
3.4. 1HNMRspectra
The 1H NMR spectrum of Hdahmp in d6-DMSO shows
two singlets at δ6.07 and 6.18ppm arising from N(4)H2 and
N(6)H2,r e s p e c t i v e l y( Scheme 1). The proton of the hydroxyl
groupO(5)Happearsasabroadsingletatδ9.13ppmandthe
N(1)H proton gives a singlet at δ7.43ppm. In the 1HN M R
spectrum of [Pd(bpy)(dahmp)]+, the proton of the hydroxyl
group is not observed while the resonance arising from
N(6)H2 is shifted to lower ﬁeld [24, 30]. Also, the resonances
arising from N(4)H2 and N(1)H are slightly shifted to lower
ﬁeld. This is probably due to the decrease in the electron
density caused by the withdrawing of electrons by the metal
ions from the pyrimidine ring coordination centers [13, 23].4 Metal-Based Drugs
Table 2: 1H NMR spectral data of Hdahmp and its complexes.
Compounds N(1)H N(4)H2 O(5)H N(6)H
Hdahmp 7.43 6.07 9.13 6.18
[Pd(bpy)(dahmp)]+ —∗ 6.08 — 6.46
[Ag(bpy)(Hdahmp)]+ —∗ 6.16 9.20 6.24
∗Signal interefered with Ph or bpy protons.
The 1HNMRspectrumof[Ag(bpy)(Hdahm)]+ conﬁrmsthe
neutral bidentate behavior of Hdahmp through the thione
sulfur and the cyclic N(3) center, as there is a slight shift
from the free ligand spectrum (Table 2). Also, the bpy lig-
and, in the complexes, shows upﬁeld shifts as compared with
[Pd(bpy)Cl2] or [Ag(bpy)(H2O)2]+. This is interpreted in
terms of strong binding of dahmp− to Pd(II) or Ag(I) in
comparison to binding of chloride and aquo species, respec-
tively [4–6].
3.5. Massspectra
The mass spectrum of [Pd(bpy)(dahmp)]Cl·H2O shows a
signal at m/e 474 (Cacld. 472.9) with 2.60% abundance. The
spectrum shows signals at 355, 215, and 129 corresponding
thelossof(H2O, C2H3N3S),(Cl,Pd)[4],and(N2,C 2H2NO)
fragments, respectively.
3.6. Thermalmeasurements
The thermal decomposition of [Pd(bpy)(dahmp)]Cl·H2O
and [Ag(bpy)(Hdahmp)]NO3 was studied by using the
thermogravimetry (TG) technique. The thermogram of
[Pd(bpy)(dahmp)]Cl·H2O shows four TG inﬂections in the
ranges 32–148, 150–360, 361–475, and 476–593◦C. The ﬁrst
weight loss may arise from the elimination of crystal lat-
tice water (Calcd. 3.81, Found 3.73%) [4]. The second step
may arise from the release of half Cl2 and C3H5N3 frag-
ments (Calcd. 25.06, Found 24.48%), the third step is due
to the removal of CNS and half bpy (C5H4N) fragments
(Calcd. 28.76, Found 29.22%) [27], while the fourth step
is attributed to the removal of the other half of bpy species
(Calcd. 16.49, Found 16.55%) followed by the formation of
PdO at 665◦C (Calcd. 25.88, Found 26.36%) [4, 27]. The
thermogram of [Ag(bpy)(Hdahmp)]NO3 shows the ﬁrst-
stepweightlossof9.29%between198and252◦C,whichcor-
responds to the release of NO2 species (Calcd. 9.51%). The
second decomposition step occurs between 253 and 352◦C,
this weight loss is attributed the loss of C3H6N3 fragment
(Calcd. 17.36, Found 17.89%). The third TG inﬂection be-
tween432–520◦C,mayarisefromtheeliminationofbpy,CS,
three quarter species (Calcd. 49.18, Found 51.09 %), leaving
Ag2O representing (Found 23.00%) [5, 27].
3.7. Conductivitymeasurements
Figure 1 shows the plots of the conductivities of [Pd(bpy)-
(dahmp)]Cl and [Ag(bpy)(Hdahmp)]NO3 against concen-
trations. It is clear that as the concentration increases, the
conductivity increases, indicating the complete ionization of
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Figure 1: Conductance-concentration relationship of the com-
plexes.
the complexes species [31]. Since the conductivity for Cl−
and NO
−
3 is 76 and 71ohmcm2,r e s p e c t i v e l y[ 31, 32], this
suggests that the complexes ionized completely in aqueous
media [33].
3.8. Anticancerousactivity
The reliable criteria for judging the eﬃcacy of any anticancer
drug are prolongation of life span, improving the clinical,
hematological, and biochemical proﬁle, as well as reduction
in viable tumor cell count in the host [34, 35]. We have re-
ported that [PdL(pa)]+, [PdL’(pa)Cl], and [Pd(bpy)(cdhp)]
(L = 2,2 -bipyridyl; L  = 9,10-phenanthroline, 2-(2 -
pyridyl)quinoxaline); pa = anion of 2-pepiridine carboxylic
acid; cdhp = dianion of 5-chloro-2,3-dihydroxypyridine) in
water or DMSO exhibit potent cytotoxic activity against
Ehrlich ascites tumor cells [4, 5]. It is known that the an-
ticancer available drugs inhibit the hematological and bio-
chemical parameters (hemoglobin (Hb), red blood cells
count (RBCs), and white blood cells count (WBCs); blood
picture).Theultimategoalofthisprojectistodevelopmixed
ligand complexes containing nitrogen bases eﬀective againstS. I. Mostafa and F. A. Badria 5
Table 3: Haematological and biochemical parameters of Hdahmp and its complexes.
Parameters
Compound Hb(1) (12–
16g/dl)
RBCs(2)
(4.0–6.0 ×
106 cell/cm3)
HCT(3)
(35.0–50.0%)
WBCs(4) (4000–
11000 ×106 cell/cm3)
EAC Count
(×106 cell/cm3)
MSt/day(5)
Hdahmp 10.7 6.3 40.3 8800 44.8 13.2
[Pd(bpy)(dahmp)]Cl 11.4 6.4 40.3 12000 31.8 11.4
[Ag(bpy)(Hdahmp)]NO3 11.0 6.3 41 9000 30.4 11.2
5-fu 10.2 6.0 37.7 7600 80 13.6
Control (0.9% NaCl) 7.8 4.72 22.2 2400 220 9.0
(1)Hb = hemoglobin, (2)RBCs = red blood cells count, (3)HCT = hemato crate value, (4)WBCs = white blood cells count values in normal mice are in paren-
theses, (5)the mean survival time.
cancer without side eﬀects on the hematological and bio-
chemical parameters.
In order to detect the inﬂuence of Hdahmp, [Pd(bpy)-
(dahmp)]Cl, and [Ag(bpy)(Hdahmp)]NO3 on the hema-
tological status of EAC-bearing mice, a comparison study
was made among three groups of mice (each group con-
tains seven mice) from the second day after inoculation.
Group (1) tumor-bearing mice treated with 5-fu (stan-
dard [36, 37]). Group (2) tumor-bearing mice treated with
Hdahmp, [Pd(bpy)(dahmp)]Cl, [Ag(bpy)(Hdahmp)]NO3.
Group (3) is the control tumor-bearing mice. The an-
ticancer activity of Hdahmp, [Pd(bpy)(dahmp)]Cl, and
[Ag(bpy)(Hdahmp)]NO3 shows remarkable eﬃcacy man-
i f e s t e db ys u r v i v a la n da c t i v i t y ,a sw e l la sr e d u c t i o ni n
the tumor size. The hematological parameters including
hemoglobin (Hb), red blood cells count (RBCs), and white
blood cells count (WBCs) data are reported in Table 3.
It is clear that the hematological parameters of tumor-
bearing mice treated with Hdahmp, [Pd(bpy)(dahmp)]Cl,
and [Ag(bpy)(Hdahmp)]NO3 exhibits much better signiﬁ-
cantﬁgureswiththeuseofsmalldosesof(0.01mg/mice/day)
compared with the standard (5-fu), the market drug
(∼0.4mg/mice/day).
There are reports that complexes containing pyridine
ring (cyclic nitrogen) display signiﬁcant anticancer activity
[4, 38]. Thus, the presence of the pyrimidine ring increases
the anticancer activity and activates the binding of metal ion
to the tumor DNA as it contains two cyclic nitrogen atoms
[5].
The hematological parameters show that [Pd(bpy)-
(dahmp)]Cl and [Ag(bpy)(Hdahmp)]NO3 are more eﬀec-
tive than Hdahmp itself, as the presence of both bpy and
dahmp in the complexes possess a multiring planar area
with nitrogen bases and hence higher hydrophobicity, which
would lead the intercalation more deeply into the tumor
DNA [5].
In order to investigate the action of Pd(II) and Ag(I)
complexes in the tumor DNA, the intercalated complexes
aﬀecting the structure of the DNA prevent polymerase and
other DNA binding proteins from functioning properly. As
thecomplexescovantelybindtoDNAwithpreferentialbind-
ing to the N-7 position of guanine and adenine, they are able
to bind two diﬀerent sites on DNA, producing cross-links
that cause increase in the viscosity in comparison to the nor-
mal unbound DNA. The results are prevention of DNA syn-
thesis, inhibition of transcription, and induction of muta-
tions [5, 39].
Regarding the tumor size and EAC count, in the control
group was (220 × 106 cells/cm3), reduced in using 5-fu to
(80×106 cells/cm3) while the strong reduction to 44.8×106,
31.8×106,a n d3 0 .4×106 cells per cm3 was observed in using
Hdahmp, [Pd(bpy)(dahmp)]+, and [Ag(bpy)(Hdahmp)]+,
respectively. The strong reduction in EAC count and tumor
size may be due to the reductive nature of many tumors that
contain signiﬁcant regions at low oxygen tension. Thus, they
initiate a catalytic auto-oxidation process involving genera-
tion of reactive oxygen species. The coordinated dahmp and
bpy may reduce toxic eﬀects caused by xenobiotic core of the
complexes, contribute to their anticancer action, and facili-
tatetheirtransportthroughcellmembrane[40].Ourinvesti-
gationshaveshownthatglutathionecontent,inliverandkid-
ney, and glutathione-S-transferase activity were decreased,
suggesting that the partial reduction products of oxygen, in
the presence of the complexes, yield very reactive species,
which could start catalytic oxidation of substrates and show
antitumor action [41].
In order to detect the inﬂuence of the solvent in the cy-
totoxicity of Hdahmp, [Pd(bpy)(dahmp)]+, and [Ag(bpy)-
(Hdahmp)]+. As expected, the water-soluble [Pd(bpy)-
(dahmp)]+ and [Ag(bpy)(Hdahmp)]+ are less kidney toxic.
3.9. Effectofsurvivaltime
The mean survival time (MST) of groups 1 and 2 was
compared with that of the control group using the fol-
lowing calculations [42]. Percentage (%) increase in lifes-
pan over control = [(MST of treated group × 100/MST
of control group) −100]; MST = days of each mice
in the group/total number of mice. Percentage (%) in-
crease in lifespan over control showed to be high in
mice treated with Hdahmp, [Pd(bpy)(dahmp)]Cl, and
[Ag(bpy)(Hdahmp)]NO3 (Table 3).
3.10. Thesideeffectsandtoxicity
T h es i d ee ﬀects and toxicity of Hdahmp, [Pd(bpy)-
(dahmp)]+, and [Ag(bpy)(Hdahmp)]+ have been detected.
After the ﬁrst week of the treatment, the mice show ﬂu-like6 Metal-Based Drugs
attack and in the third week show spot dropping on the hair
(alopecia). Fortunately, the solid organs have not been af-
fected.
The study of detailed mechanism and in vivo anticancer
screens (phase II & III) using the studied complexes are un-
der way.
4. CONCLUSION
There are reports that complexes containing pyridine ring
(cyclic nitrogen) display signiﬁcant anticancer activity. The
anticancer activity of the new water-soluble complexes,
[Pd(bpy)(dahmp)]Cl and [Ag(bpy)(Hdahmp)]NO3, shows
remarkable eﬃcacy against Ehrlich ascitestumor cells (EACs)
manifestedbysurvivalandactivity,aswellasreductioninthe
tumor size.
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